Stevens Capital Management’s Corcept Therapeutics CORT Stock Holding History

Stevens Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-13,593	Closed	-$214K	–	760
2018 Q2	$214K	Buy	+13,593	New	+$236K	0.01%	691
2017 Q1	–	Sell	-19,096	Closed	-$139K	–	898
2016 Q4	$139K	Buy	+19,096	New	+$150K	0.01%	802
2016 Q3	–	Sell	-17,323	Closed	-$95K	–	935
2016 Q2	$95K	Buy	+17,323	New	+$90.1K	﹤0.01%	836
2015 Q4	–	Sell	-27,694	Closed	-$104K	–	953
2015 Q3	$104K	Buy	+27,694	New	+$141K	﹤0.01%	897

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Stevens Capital Management's CORT Position: Q3 2018 in Review

Stevens Capital Management sold out of Corcept Therapeutics (CORT) in Q3 2018, closing a stake of 13,593 shares — an estimated $214K sold.

Stevens Capital Management first reported a position in CORT in Q3 2015 and held it in 4 quarters. The position peaked at $214K in Q2 2018. 207 funds tracked by Wall St. Rank hold CORT as of Q3 2018.

Stevens Capital Management reported no remaining Corcept Therapeutics position as of Q3 2018 after selling out during the quarter.
Stevens Capital Management sold 13,593 Corcept Therapeutics shares in Q3 2018, an estimated $214K.
Stevens Capital Management first reported a position in Corcept Therapeutics in Q3 2015 and held it in 4 quarters.
Stevens Capital Management's Corcept Therapeutics position peaked at $214K in Q2 2018.
207 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2018.

Based on Stevens Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.